Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inhibiton Therapeutics has reported that its ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines.
Subscribe to our email newsletter
The present work performed under a co-operative research and development agreement (CRADA) with the Department of Veteran’s Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.
Further in-vitro studies investigating the effects of ICA-1 on breast cancer cells have also obtained promising results. ICA-1 was effective in reducing the proliferation of MDA-MB-468 breast cancer cells by 83% compared to controls when incubated with the drug for 48 hours at clinical concentrations. For MCF-7 breast cancer cells, ICA-1 was effective in reducing the proliferation by 32% compared to controls when treated with the drug for 24 hours. These results indicate that ICA-1 has promising results for further in-vitro studies as well as future in-vivo studies for the potential treatment of breast cancer as well as neuroblastoma.
The company’s research is being performed under the VA CRADA at the James Haley Veterans’s Hospital in Tampa, Florida, in conjunction with the University of South Florida.